A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor

PloS one, Volume 13, Issue 12, 2018, Pages 1-12.

Cited by: 10|Bibtex|Views123|DOI:https://doi.org/10.1371/journal.pone.0208422
WOS
Other Links: pubmed.ncbi.nlm.nih.gov|academic.microsoft.com

Abstract:

Checkpoint inhibitor immunotherapies have had major success in treating patients with late-stage cancers, yet the minority of patients benefit. Mutation load and PD-L1 staining are leading biomarkers associated with response, but each is an imperfect predictor. A key challenge to predicting response is modeling the interaction between the...More

Code:

Data:

Full Text
Your rating :
0

 

Tags
Comments